Sun Pharma Partners Hypera Pharma to Launch Semaglutide in Brazil After ANVISA Nod
Mumbai: Sun Pharmaceutical Industries Limited has received approval from the Brazilian Health Regulatory Agency (ANVISA) to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Sun Pharma said it plans to launch the product in the coming days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. The product will be available as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—allowing flexible, once-weekly dosing.
"The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high-quality medicines across global markets," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.
Commenting on the development, Digvijay Singh, Regional Head, Brazil & LATAM, said, "This approval marks an important step in strengthening our diabetes portfolio in Brazil. We look forward to working closely with our partner to make this treatment option available to patients and support better diabetes care across the country."
According to IQVIA MAT June 2026 data cited by the company, the semaglutide injectable market in Brazil is valued at approximately USD 413 million.
Sun Pharma is a global pharmaceutical company with operations spanning innovative medicines, generics, and consumer healthcare products. It is India's largest pharmaceutical company and has a significant presence in the U.S. generics market and other global emerging markets. Its innovative medicines portfolio focuses on dermatology, ophthalmology, and oncodermatology, while its products are marketed in more than 100 countries.
